PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277821
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Iodine Content Analysis Using Dual-Energy Computed Tomography as a Biomarker of
      Transitional Cell Carcinoma, an Experience with Separation of the Clotted Blood
      and Tumorous Tissue.
PG  - 541-545
AB  - BACKGROUND/AIM: The aim of this study was to evaluate the possibility to
      discriminate the blood clot from tumorous tissue in the assessment of
      transitional cell carcinoma (TCC), when CT data are used only from single-phase
      dual-energy CT (DECT). MATERIALS AND METHODS: A total of 18 patients were
      included into the retrospective analysis of the prospectively collected data (the
      average age was 67.3 years, range=62-79 years, 12 males, 6 females). DECT was
      performed in all patients after intravenous administration of the iodinated
      contrast material. DECT analysis using three-material decomposition algorithm was
      used to discriminate blood and enhancing tumorous tissue. In all patients, TCC
      was detected and subsequently kidney surgery or endoscopy was performed within
      the next two weeks. The findings were compared with DECT results. RESULTS: In our
      cohort of patients we found 9 TCC of the renal pelvis or ureter and 7 TCC of the 
      urinary bladder. The accuracy of the TCC detection was 94% (17/18). The presence 
      of coagulated blood within the urinary collecting system together with a tumor
      was detected in 7 CT examinations. The blood coagulum without a confirmed
      malignant tumor was found in one case with false positive DECT finding. In other 
      6 cases bleeding was confirmed during surgery or endoscopy (accuracy 87%).
      CONCLUSION: The dual-energy data analysis enables discrimination of a blood clot 
      from tumorous tissue. It helps in detection of UCC in cases when the excretion
      potential of the kidneys is decreased due to fulfillment of the collecting system
      with blood clots.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Mirka, Hynek
AU  - Mirka H
AD  - Department of Imaging Methods, Medical School and Teaching Hospital Pilsen,
      Charles University in Prague, Pilsen, Czech Republic [email protected]
AD  - Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague,
      Pilsen, Czech Republic.
FAU - Baxa, Jan
AU  - Baxa J
AD  - Department of Imaging Methods, Medical School and Teaching Hospital Pilsen,
      Charles University in Prague, Pilsen, Czech Republic.
FAU - Hora, Milan
AU  - Hora M
AD  - Department of Urology, Medical School and Teaching Hospital Pilsen, Charles
      University in Prague, Pilsen, Czech Republic.
FAU - Hes, Ondrej
AU  - Hes O
AD  - Sikl's Department of Pathology, Medical School and Teaching Hospital Pilsen,
      Charles University in Prague, Pilsen, Czech Republic.
FAU - Topolcan, Ondrej
AU  - Topolcan O
AD  - Central Laboratory for Immunoanalysis, Medical School and Teaching Hospital
      Pilsen, Charles University in Prague, Pilsen, Czech Republic.
FAU - Ferda, Jiri
AU  - Ferda J
AD  - Department of Imaging Methods, Medical School and Teaching Hospital Pilsen,
      Charles University in Prague, Pilsen, Czech Republic.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - Dual-energy CT
OT  - hematuria
OT  - transient cell carcinoma
OT  - urinary tract tumors
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/26 00:00 [received]
PHST- 2017/11/11 00:00 [revised]
PHST- 2017/11/13 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/541 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):541-545.